Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FBT-SP101
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
01
Overview
FBT-SP101 is a small molecule drug candidate being developed by Fusion Biotech for the treatment of dry age-related macular degeneration (dry AMD). It is designed to act as a reactive oxygen species (ROS) inducer. FBT-SP101 is currently in the research stage of development.
02
Targets
ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on FBT-SP101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FBT-SP101.